Next pandemic risk: Woman dies after infection with two Covid-19 variants

Belgian researchers couldn't say whether co-infection played a role in the 90-year-old's deterioration.

vaccine, coronavirus, covid-19, research, medical, healthcare, R&D, manufacturing, Drugs Laboratory
The idea of multiple infections isn’t completely new; cases suggest co-infection might be more common than currently known. (File photo.)
Suzi Ring | Bloomberg
2 min read Last Updated : Jul 11 2021 | 5:52 AM IST
A 90-year-old woman died after becoming infected with two different strains of Covid-19, revealing another risk in the fight against the disease, Belgian researchers found.

In the first peer-reviewed analysis of an infection with multiple strains, scientists found the woman had contracted both the alpha variant, which first surfaced in the U.K., and the beta strain, first found in South Africa. The infections probably came from separate people, according to a report published Saturday and presented at the European Congress of Clinical Microbiology & Infectious Diseases.

The woman was admitted to a Belgian hospital in March after a number of falls, and tested positive for Covid-19 the same day. She lived alone, receiving nursing care at home, and hadn’t been vaccinated. Her respiratory symptoms rapidly worsened and she died five days later. When her respiratory samples were tested for variants of concern, both strains were found in two tests. The researchers couldn’t say whether the co-infection played a role in her rapid deterioration.

The idea of multiple infections isn’t completely new. In January, Brazilian scientists reported two cases of Covid-19 co-infection, but the study hasn’t yet been released in a scientific journal. Researchers have also previously found evidence of people becoming infected with multiple strains of influenza. The cases suggest co-infection might be more common than currently known.

“The global occurrence of this phenomenon is probably underestimated due to limited testing for variants of concern and the lack of a simple way to identify co-infections with whole genome sequencing,” said Anne Vankeerberghen, the lead author of the study and a molecular biologist from OLV Hospital in Aalst, Belgium. “Being alert to co-infections remains crucial.”

Such instances also raise questions over how much protection vaccines can provide. With the rapidly spreading delta variant now the dominant strain in many places, including the U.K., drugmakers are rushing to test their shots against variants and create new versions that could provide a better defense. Countries are also mulling whether to offer booster shots this winter to guard against diminishing responses from vaccines.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineCoronavirus Tests

Next Story